Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : KCAP - Key Capital Corporation -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (17)	6/15/1998 7:37:00 PM
From: ACC	Read Replies (2) \| Respond to of 459

<<Something is not right here. Those Phase I references are very old. >> richard, i absolutely agree with you... i posted those references because i agreed with Your Highness' cautionary comments: Message 4849387 The text of the 504 was rather vague about details not of the offering, but of the science behind the offering. I used the Entrez browser- www3.ncbi.nlm.nih.gov to try to track down any info about the scientist driving CRS (RW Urban) and/or the product "NPP5". It is possible I missed some later Phase 1 data, but i don't think so... if you search under "ImuVert" there are recent citations, mostly researchers looking at the immunomodulatory effects, but nothing more recent regarding clinical trials. There is a reference in a nursing journal that mentions a Phase II - I haven't pulled the article to see if the authors actually cite any reference to that trial. As for Dr. Urban's publications, the phase I trial he appears to be involved in indeed was published in 1992. So... draw your conclusions. Furthermore, ImuVert appears to be a liposomal preparation from bacteria (Gram negative Serratia, FWIW)... so basically, it nonspecifically turns up the immune response. It might work... although I'm partial to the anti-angiogenic approach, which also remains to be proven, but just seems more elegant - I just lucked out. If a hapless reporter hadn't cornered Watson over hors d'oeuvres, ENMD would still be parked at 8-15/share, which is where it probably (unfortunately) will wind up. When? I haven't a clue. So, after a very long-winded reply, I agree with zgoodman that ENMD is overvalued. KCAP/CRS may very well be undervalued, but I would be more comfortable taking the leap if there were more data published, or some additional investigational drugs in development. IMHO ACC